H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics (NASDAQ: INKT) from Buy to Neutral.The analyst comments "Dual-function of iNKT cells ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE